STAGE III BREAST CANCER AJCC V7
Clinical trials for STAGE III BREAST CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE III BREAST CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE III BREAST CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo for advanced breast cancer falls short
Disease control TerminatedThis study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and targeted therapy could help people with HER2-positive breast cancer that has spread. The trial included 190 adults with advanced disease. Unfortunately, the study was stopped early, …
Matched conditions: STAGE III BREAST CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Breast cancer drug combo shows promise but study halted early
Disease control TerminatedThis study tested a mix of targeted drugs (neratinib, pertuzumab, trastuzumab) and chemotherapy (paclitaxel) in people with advanced or inflammatory breast cancer. The goal was to find the best dose and see if the combination could shrink tumors before more chemo. The study was s…
Matched conditions: STAGE III BREAST CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New drug cocktail trial targets tough cancers and rare diseases
Disease control TerminatedThis early-phase study tested combinations of three drugs—bevacizumab, temsirolimus, and either valproic acid or cetuximab—in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find the safest dose and see how well the drugs w…
Matched conditions: STAGE III BREAST CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 02, 2026 11:39 UTC